Compare Eli Lilly And Co (LLY) vs NetFlix Inc (NFLX) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Netflix (NFLX) trades at $74.79, down 1.97% amid a recent losing streak, yet maintains strong fundamentals with 28.22% net margins and consistent earnings beats. The stock shows bullish technical signals with support at $72-$74 levels, while analyst consensus remains positive with a $90.45 price target. Revenue growth accelerated to $45.18B in 2025, supported by expanding ad-tier adoption and content investments.

Investment outlook remains favorable given Netflix's dominant streaming position and ad revenue potential, though risks include increased competition and execution challenges in new initiatives. Wall Street's 63% buy rating reflects confidence in the company's ability to maintain growth momentum despite recent price weakness.